As described under "Packaging" on the Product Detail Page, this product is supplied in 1.005 mg quantities.
Sign In to View Organizational & Contract Pricing.
About This Item
Empirical Formula (Hill Notation):
C22H17ClN2
CAS Number:
Molecular Weight:
344.84
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
Skip To
InChI
1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H
SMILES string
Clc1ccccc1C(c2ccccc2)(c3ccccc3)n4ccnc4
InChI key
VNFPBHJOKIVQEB-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
clotrimazole
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
1 of 4
This Item | BP379 | C6019 | C2430000 |
|---|---|---|---|
| manufacturer/tradename EDQM | manufacturer/tradename BP | manufacturer/tradename - | manufacturer/tradename EDQM |
| grade pharmaceutical primary standard | grade pharmaceutical primary standard | grade - | grade pharmaceutical primary standard |
| format neat | format neat | format - | format neat |
| application(s) pharmaceutical (small molecule) | application(s) pharmaceutical | application(s) - | application(s) pharmaceutical (small molecule) |
| API family clotrimazole | API family clotrimazole | API family - | API family clotrimazole |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. - | storage temp. - |
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Clotrimazole for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
comparable product
Product No.
Description
Pricing
related product
Product No.
Description
Pricing
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2 - Skin Irrit. 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Natalia Mast et al.
Molecular pharmacology, 84(1), 86-94 (2013-04-23)
Although there are currently three generations of antifungal azoles on the market, even the third-generation agents show undesirable interactions with human cytochrome P450 (P450) enzymes. CYP46A1 is a cholesterol-metabolizing P450 in the brain that tightly binds a number of structurally
Maria F Sassano et al.
Journal of medicinal chemistry, 56(6), 2406-2414 (2013-02-27)
Colloidal aggregation is the dominant mechanism for artifactual inhibition of soluble proteins, and controls against it are now widely deployed. Conversely, investigating this mechanism for membrane-bound receptors has proven difficult. Here we investigate the activity of four well-characterized aggregators against
Jenna Corcoran et al.
Aquatic toxicology (Amsterdam, Netherlands), 152, 57-65 (2014-04-15)
Clotrimazole (CTZ) is a persistent imidazole antifungal agent which is frequently detected in the aquatic environment and predicted to bio-concentrate in fish. Common carp (Cyprinus carpio) were exposed to mean measured concentrations of either 1.02 or 14.63μgl(-1) CTZ for 4
Laura Ravani et al.
International journal of pharmaceutics, 454(2), 695-702 (2013-06-25)
The aim of the present work is to design a new formulation containing clotrimazole (CTZ) loaded into nanostructured lipid carriers (NLC) for the treatment of fungal vaginal infections. In order to obtain formulations with suitable viscosity for mucosal application, NLC
Sandra Gemma et al.
Journal of medicinal chemistry, 55(15), 6948-6967 (2012-07-13)
Despite recent progress in the fight against malaria, the emergence and spread of drug-resistant parasites remains a serious obstacle to the treatment of infections. We recently reported the development of a novel antimalarial drug that combines the 4-aminoquinoline pharmacophore of
-
pack size, please
1 answer-
Helpful?
-
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service